Bio/Pharma News

J&J Announces Compassionate Care Committee in Collaboration with NYU

May 07, 2015

Johnson & Johnson announces partnership with NYU School of Medicine to launch a compassionate care committee for individual patient requests of investigational drugs.

Court Blocks First FDA-Approved Biosimilar, for the Time Being

May 07, 2015

The US Court of Appeals granted Amgen’s request to block Novartis’ Neupogen biosimilar, Zarxio, from the US market until the court resolves litigation between the two companies.

Alexion Acquires Synageva for $8.4 Billion

May 06, 2015

Alexion announces it will expand its rare disease pipeline with a definitive agreement to acquire Synageva.

Biosimilar Giants Launch Biosimilars Forum

May 06, 2015

Eleven of the leading US biosimilar developers have collaborated to form the Biosimilars Forum, a nonprofit organization formed to expand patient access to biosimilars.

Teva Parenteral Medicines Recalls Adrucil

May 06, 2015

The company voluntarily recalls select lots of Adrucil due to particulate matter.

Bayer Buys Rights to Isis Pharma’s Blood Thinner for Up to $155 Million

May 04, 2015

Bayer announces that it will pay up to $155 million, plus royalties, for the rights to Isis Pharma’s anti-clotting drug, ISIS-FXI.

Novo Nordisk Invests DKK1.5 Billion in New Manufacturing Facility

May 04, 2015

Novo Nordisk announces that it will invest DKK1.5 billion (US$224 million) in a haemophilia treatment manufacturing facility in Denmark.

Biosimilars Will Bring Significant Litigation and Patent Challenges

May 04, 2015

Intellectual property lawyers estimate biosimilar litigation will swell as early as 2018.

Congress Encourages Modern Drug Manufacturing

May 01, 2015

The revised "21st Century Cures” proposal includes provisions for research for continuous manufacturing, biomarker development, and NIH funding.

The Acquisition Battle Continues with Another Perrigo Rejection

April 30, 2015

Perrigo rejected Mylan’s second proposal for an acquisition valued at more than $34 billion, saying that the offer was too low to consider.